GPR183 and metabolic dysfunction-associated steatohepatitis: We report no effect of EBI2, CH25H, or CYP7B1 knockouts in the complex mechanisms of steatosis and inflammation during NASH pathogenesis, making essential effects of EBI2 or its ligand 7α,25-diHC in NAFLD/NASH highly unlikely.